Otezla and Injection site mass - a phase IV clinical study of FDA data

Summary:

Injection site mass is reported as a side effect among people who take Otezla (apremilast), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Enbrel, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Injection site mass when taking Otezla. It is created by eHealthMe based on reports of 146,032 people who have side effects when taking Otezla from the FDA, and is updated regularly.

What is Otezla?

Otezla has active ingredients of apremilast. It is often used in psoriatic arthritis. eHealthMe is studying from 146,254 Otezla users. Check the latest studies of Otezla.

What is Injection site mass?

Injection site mass is found to be associated with 832 drugs and 787 conditions by eHealthMe. Check the latest studies of Injection site mass.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

146,032 people reported to have side effects when taking Otezla.
Among them, 17 people (0.01%) have Injection site mass.

Among these 17 people:

How long have people been on Otezla when they have Injection site mass? *

What is the gender of people who have Injection site mass when taking Otezla? *

female: 76.47 %
male: 23.53 %

What is the age of people who have Injection site mass when taking Otezla? *

What are other drugs people take besides Otezla? *

What are other side effects people have besides Injection site mass? *

Injection Site Pain: 7 people, 41.18%
Injection Site Pruritus (severe itching at injection site): 6 people, 35.29%
Injection Site Haemorrhage (bleeding from injection site): 4 people, 23.53%
Psoriasis (immune-mediated disease that affects the skin): 4 people, 23.53%
Injection Site Erythema (redness at injection site): 4 people, 23.53%
Feeling Abnormal: 3 people, 17.65%
Injection Site Bruising: 3 people, 17.65%
Injection Site Warmth: 3 people, 17.65%
Nail Abnormalities (abnormal nail): 3 people, 17.65%
Nausea (feeling of having an urge to vomit): 3 people, 17.65%

What are the existing conditions these people have? *

Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 7 people, 41.18%
Psoriasis (immune-mediated disease that affects the skin): 6 people, 35.29%
Immunodeficiency Common Variable: 2 people, 11.76%
Urticaria (rash of round, red welts on the skin that itch intensely): 1 person, 5.88%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.88%
Restless Leg Syndrome (a powerful urge to move your legs): 1 person, 5.88%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 5.88%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.88%
High Blood Cholesterol: 1 person, 5.88%
Glucose Tolerance Impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Otezla and have Injection site mass?

- Check whether Injection site mass is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Otezla:

Otezla (146,254 reports)

Browse all side effects of Otezla:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site mass:

Injection site mass (832 drugs)

Browse all the conditions that are associated with Injection site mass:

Injection site mass (787 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on apremilast (the active ingredients of Otezla) and Otezla (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.